SCHEMBL21814280

SCHEMBL21814280

CC1CCCN(CCCOc2ccc(N)cc2)C1

nearest known ligand 0.78

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 17/20 0.73
MAOB P27338 2/20 0.68
HRH2 P25021 1/20 0.68
HRH1 P35367 1/20 0.68
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473444 1.00 HRH3 (0.73) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL21814266 0.92 SIGMAR1 (0.62) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL4094728 0.86 KDM4E (0.87) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL14591695 0.86 HRH3 (0.85) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL12062205 0.84 HRH3 (1.00) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL4095149 0.84 HRH3 (1.00) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL12061360 0.84 HRH3 (0.81) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL4095152 0.84 HRH3 (1.00) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL491736 0.84 HRH3 (0.93) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL15925684 0.84 HRH3 (0.70) HRH3MAOBHRH2HRH1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12172980-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XWPharma Ltd. (KY) 2024-12-24 US disclosed
EP-3856719-B1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPHARMA LTD (KY) 2023-06-07 EP disclosed
US-20220380339-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2022-12-01 US disclosed
US-11420955-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XWPharma Ltd. (KY) 2022-08-23 US disclosed
US-20210188808-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2021-06-24 US disclosed
US-10968202-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. (KY) 2021-04-06 US disclosed
US-20200369645-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2020-11-26 US disclosed
US-10730853-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. (KY) 2020-08-04 US disclosed
US-20200181112-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2020-06-11 US disclosed
US-10618886-B1 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. (KY) 2020-04-14 US disclosed
US-20200102289-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2020-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102289-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-20220380339-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAOB 282/4885HRH2 3/4885
US-20200181112-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-10618886-B1 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-12172980-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-10968202-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-20200369645-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-20210188808-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-11420955-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885
US-10730853-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885MAOB 266/4885HRH2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.